Early in her tenure, Federal Trade Commission (the "FTC") Chair Lina Khan vowed to take a "muscular" approach to regulating U.S. private equity dealmaking. Recent events, such as the FTC's targeting of roll-ups, make clear, more than ever before, that U.S. private equity buyers should consider antitrust strategy when seeking to get deals done.
On September 21, 2023, in the current administration's first litigated case challenging serial acquisitions by a private equity firm, the FTC challenged Welsh, Carson, Anderson & Stowe's ("Welsh Carson") roll-up strategy of anesthesiology practices across Texas. The FTC brought suit against Welsh Carson and its partially owned portfolio company, U.S. Anesthesia Partners, Inc. ("USAP"), in Texas federal court, accusing them of using a roll-up scheme to systemically acquire "nearly every large anesthesia practice in Texas to create a single dominant provider with the power to demand higher prices." That same day, Chair Khan said in a statement that "the FTC will continue to scrutinize and challenge serial acquisitions, roll-ups, and other stealth consolidation schemes that unlawfully undermine fair competition and harm the American public." The FTC's complaint seeks "structural relief," presumably including divestitures to effectively unwind the acquisitions and to enjoin the defendants from engaging in similar conduct (potentially not limited to Texas and not just with respect to anesthesiology practices).
One of the most interesting facts about this challenge is that Welsh Carson formed USAP back in 2012, with the roll-up acquisitions in question occurring between 2012 and 2020, the vast majority of which took place prior to 2017 and likely all of which were of a deal value below the threshold requiring a Hart-Scott-Rodino ("HSR") filing. USAP has been operating in its "rolled-up" form for years, so why is the FTC now asserting that the acquisitions were illegal "whether considered individually or as a series?"
It doesn't help that private equity buyers are on the administration's stated agenda. In June 2022, Chair Khan issued a statement calling out private equity firms and their serial acquisitions in the healthcare industry, highlighting the following sectors: anesthesiology, emergency medicine, hospice care, air ambulances, and opioid treatment centers. The takeaway here is that even non-reportable transactions that closed years ago may get attention from today's U.S. antitrust agencies, particularly those involved in a roll-up strategy in any of the named healthcare sectors.
Visit us at mayerbrown.com
Mayer Brown is a global services provider comprising associated legal practices that are separate entities, including Mayer Brown LLP (Illinois, USA), Mayer Brown International LLP (England & Wales), Mayer Brown (a Hong Kong partnership) and Tauil & Chequer Advogados (a Brazilian law partnership) and non-legal service providers, which provide consultancy services (collectively, the "Mayer Brown Practices"). The Mayer Brown Practices are established in various jurisdictions and may be a legal person or a partnership. PK Wong & Nair LLC ("PKWN") is the constituent Singapore law practice of our licensed joint law venture in Singapore, Mayer Brown PK Wong & Nair Pte. Ltd. Details of the individual Mayer Brown Practices and PKWN can be found in the Legal Notices section of our website. "Mayer Brown" and the Mayer Brown logo are the trademarks of Mayer Brown.
© Copyright 2023. The Mayer Brown Practices. All rights reserved.
This Mayer Brown article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.